Previous Close | 0.6183 |
Open | 0.6101 |
Bid | 0.5902 x 3200 |
Ask | 0.5986 x 900 |
Day's Range | 0.5850 - 0.6240 |
52 Week Range | 0.3650 - 0.9650 |
Volume | |
Avg. Volume | 1,039,655 |
Market Cap | 119.668M |
Beta (5Y Monthly) | 0.86 |
PE Ratio (TTM) | 1.79 |
EPS (TTM) | 0.3300 |
Earnings Date | Feb 27, 2023 - Mar 03, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 0.60 |
Subscribe to Yahoo Finance Plus to view Fair Value for SESN
CAMBRIDGE, Mass., January 30, 2023--Sesen Bio, Inc. (Nasdaq: SESN) ("Sesen Bio" or the "Company") today announced that it has received notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") that, based upon the Company’s non-compliance with the $1.00 bid price requirement for continued listing on The Nasdaq Capital Market, the Company’s common stock is subject to delisting.
CAMBRIDGE, Mass., January 26, 2023--Sesen Bio, Inc. (Nasdaq: SESN) today issued the following statement reiterating the Company’s confidence in, and commitment to, the pending merger with Carisma Therapeutics Inc. (Carisma) in response to the release issued yesterday by Bradley Radoff and Michael Torok and their affiliates (collectively, the "Investor Group"):
HOUSTON, January 25, 2023--Bradley L. Radoff and Michael Torok (together with their affiliates, the "Investor Group" or "we"), who own approximately 8.4% of the outstanding common stock of Sesen Bio, Inc. (Nasdaq: SESN) ("Sesen Bio"), today issued the following open letter to the Boards of Directors (collectively, the "Boards") of Sesen Bio and Carisma Therapeutics Inc. ("Carisma" and together with Sesen Bio, the "Companies"):